HOME
CONTACT
News
ALL
V-Bio News
Portfolio News
Newsletter
V-Bio Ventures leads AgomAb Therapeutics’ Euros 21m Series A Financing
v-bio-ventures
2019-04-03T08:21:45+00:00
April 3rd, 2019
|
V-Bio News
|
Read More
V-Bio Ventures Newsletter February 2019
v-bio-ventures
2019-02-11T11:37:28+00:00
February 8th, 2019
|
Newsletter
|
Read More
V-Bio Ventures leads Camel-IDS EUR 37m Series A financing to develop cancer targeted radiopharmaceuticals
v-bio-ventures
2018-11-27T19:46:39+00:00
November 15th, 2018
|
V-Bio News
|
Read More
V-Bio Ventures Newsletter October 2018
v-bio-ventures
2018-10-03T09:59:26+00:00
October 3rd, 2018
|
Newsletter
|
Read More
V-Bio Ventures participates in 22.5 million euros series B financing round of HORAMA
v-bio-ventures
2018-09-20T10:11:13+00:00
September 18th, 2018
|
V-Bio News
|
Read More
V-Bio Ventures Newsletter june 2018
v-bio-ventures
2018-06-08T16:01:23+00:00
June 8th, 2018
|
Newsletter
|
Read More
V-Bio Ventures Newsletter march 2018
v-bio-ventures
2018-03-11T08:39:41+00:00
March 11th, 2018
|
Newsletter
|
Read More
Syndesi Therapeutics announces appointment of experienced management team to lead development of novel pro-cognitive SV2A modulators
v-bio-ventures
2018-03-05T15:35:45+00:00
March 1st, 2018
|
Portfolio News
|
Read More
V-Bio Ventures invests in UCB spinout Syndesi Therapeutics to develop novel therapeutics for cognitive disorders
v-bio-ventures
2018-03-11T08:34:49+00:00
February 1st, 2018
|
V-Bio News
|
Read More
Confo Therapeutics enters into drug discovery collaboration with Roche
v-bio-ventures
2017-12-19T10:34:17+00:00
December 19th, 2017
|
Portfolio News
|
Read More
OCTIMET Oncology NV awarded €1.12 million grant from VLAIO
v-bio-ventures
2017-11-07T08:32:48+00:00
November 7th, 2017
|
Portfolio News
|
Read More
Confo Therapeutics enters into drug discovery collaboration with Lundbeck
v-bio-ventures
2017-10-09T09:31:33+00:00
September 26th, 2017
|
Portfolio News
|
Read More
V-Bio Ventures Newsletter sept 2017
v-bio-ventures
2017-09-26T15:16:55+00:00
September 21st, 2017
|
Newsletter
|
Read More
Octimet: Dosing of First Patient with investigational agent OMO-1
v-bio-ventures
2017-10-09T09:22:39+00:00
August 25th, 2017
|
Portfolio News
|
Read More
V-Bio Ventures leads EUR 7.7M financing of Aphea.Bio
v-bio-ventures
2017-10-09T09:22:31+00:00
June 16th, 2017
|
V-Bio News
|
Read More
V-Bio Ventures invests in OCTIMET Oncology
v-bio-ventures
2017-10-09T09:22:27+00:00
January 19th, 2017
|
V-Bio News
|
Read More
Oxular Appoints David Fellows as Chairman of the Board
v-bio-ventures
2017-10-13T15:30:44+00:00
January 11th, 2017
|
Portfolio News
|
Read More
V-Bio Ventures closes first life sciences fund, raising over € 75 million
v-bio-ventures
2017-10-09T09:22:18+00:00
December 1st, 2016
|
V-Bio News
|
Read More
Confo Therapeutics appoints Dr. Cedric Ververken as Chief Executive Officer
v-bio-ventures
2017-10-09T09:32:12+00:00
September 6th, 2016
|
Portfolio News
|
Read More
Precision Ocular Ltd Completes £15.5 million Series A Financing V-Bio Ventures joins investment syndicate
v-bio-ventures
2017-10-09T09:22:09+00:00
July 19th, 2016
|
Portfolio News
|
Read More
Confo Therapeutics appoints Dr Christel Menet as Chief Scientific Officer
v-bio-ventures
2017-10-09T09:22:04+00:00
May 10th, 2016
|
Portfolio News
|
Read More
V-Bio Ventures invests in VIB spinout Confo Therapeutics NV
v-bio-ventures
2017-10-09T09:21:58+00:00
February 2nd, 2016
|
V-Bio News
|
Read More
First Closing of V-Bio Ventures Fund 1 with commitments of € 63 million
v-bio-ventures
2017-10-13T15:24:37+00:00
November 19th, 2015
|
V-Bio News
|
Read More
